Dr. Bhagwan Yadav, PhD

Citée par

	Toutes	Depuis 2019
Citations	3377	2664
indice h	27	25
indice i10	33	31

580

290

145

435

2014201520162017201820192020202120222023202449 64 118 192 252 347 458 563 541 550 203

Accès public

Tout afficher

32 articles

3 articles

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Tero AittokallioUniversity of Helsinki, University of Turku, University of OsloAdresse e-mail validée de utu.fi
Caroline HeckmanUniversity of Helsinki, Institute for Molecular Medicine Finland FIMM-HiLIFEAdresse e-mail validée de helsinki.fi
Olli KallioniemiDirector, Science for Life Laboratory and the data-driven life science programAdresse e-mail validée de scilifelab.se
Kimmo PorkkaProfessor of hematology, Helsinki University Hospital Cancer CenterAdresse e-mail validée de helsinki.fi
Mika KontroHelsinki University Hospital and Institute for Molecular Medicine FinlandAdresse e-mail validée de helsinki.fi
Krister WennerbergBRIC, University of CopenhagenAdresse e-mail validée de fimm.fi
MM MajumderInstitute for Molecular Medicine Finland(FIMM), University of HelsinkiAdresse e-mail validée de fimm.fi
Tea Pemovska, PhDSenior Postdoctoral Researcher at Medical University of ViennaAdresse e-mail validée de meduniwien.ac.at
Evgeny KulesskiyUniversity of Helsinki,Adresse e-mail validée de helsinki.fi
Riikka KarjalainenAdresse e-mail validée de helsinki.fi
Disha MalaniInstitute for Molecular Medicine Finland (FIMM), University of HelsinkiAdresse e-mail validée de helsinki.fi
Jing TangAssociate professor, University of HelsinkiAdresse e-mail validée de helsinki.fi
Satu MustjokiUniversity of HelsinkiAdresse e-mail validée de helsinki.fi
Bjorn T. GjertsenProfessor of Hematology, University of BergenAdresse e-mail validée de uib.no
Ashwini KumarSenior Scientist Johnson & Johnson R&DAdresse e-mail validée de helsinki.fi
Samuli Eldfors, PhDResearch Fellow, MGH, Harvard Medical SchoolAdresse e-mail validée de mgh.harvard.edu
Prson Gautam, PhDVisiting Researcher, Institute for Molecular Medicine Finland, University of HelsinkiAdresse e-mail validée de helsinki.fi
Swapnil PotdarBioinformatics Researcher, Institute for Molecular Medicine, FinlandAdresse e-mail validée de helsinki.fi
Päivi ÖstlingScientific Lead of Precision Medicine, SciLifeLab, Dept. Oncology and Pathology, KarolinskaAdresse e-mail validée de ki.se
David TamboreroAdresse e-mail validée de scilifelab.se

Suivre

Dr. Bhagwan Yadav, PhD

University of Helsinki

Adresse e-mail validée de helsinki.fi

Data Scientist Bioinformatics Specialist


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model B Yadav, K Wennerberg, T Aittokallio, J Tang Computational and Structural Biotechnology Journal 13, 504-513, 2015	584	2015
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid LeukemiaISM Approach to Therapy Selection T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ... Cancer discovery 3 (12), 1416-1429, 2013	447	2013
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies B Yadav, T Pemovska, A Szwajda, E Kulesskiy, M Kontro, R Karjalainen, ... Scientific reports 4 (1), 1-10, 2014	320	2014
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells O Kauko, CM O’Connor, E Kulesskiy, J Sangodkar, A Aakula, S Izadmehr, ... Science translational medicine 10 (450), eaaq1093, 2018	142	2018
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target O Dufva, M Kankainen, T Kelkka, N Sekiguchi, SA Awad, S Eldfors, ... Nature Communications 9 (1), 1567, 2018	128	2018
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia H Kuusanmäki, AM Leppä, P Pölönen, M Kontro, O Dufva, D Deb, ... Haematologica 105 (3), 708, 2020	126	2020
JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML R Karjalainen, T Pemovska, M Popa, M Liu, KK Javarappa, MM Majumder, ... Blood, The Journal of the American Society of Hematology 130 (6), 789-802, 2017	122	2017
Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection OV Denisova, L Kakkola, L Feng, J Stenman, A Nagaraj, J Lampe, ... Journal of Biological Chemistry 287 (42), 35324-35332, 2012	101	2012
Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways J Tang, L Karhinen, T Xu, A Szwajda, B Yadav, K Wennerberg, ... PLoS computational biology 9 (9), e1003226, 2013	96	2013
Comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancer K Saeed, V Rahkama, S Eldfors, D Bychkov, JP Mpindi, B Yadav, ... European urology 71 (3), 319-327, 2017	95	2017
Consistency in drug response profiling JP Mpindi, B Yadav, P Östling, P Gautam, D Malani, A Murumägi, ... Nature 540 (7631), E5-E6, 2016	95	2016
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL A Schrader, G Crispatzu, S Oberbeck, P Mayer, S Pützer, J von Jan, ... Nature communications 9 (1), 1-22, 2018	89	2018
HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia M Kontro, A Kumar, MM Majumder, S Eldfors, A Parsons, T Pemovska, ... Leukemia 31 (2), 301-309, 2017	89	2017
Breeze: an integrated quality control and data analysis application for high-throughput drug screening S Potdar, A Ianevski, JP Mpindi, D Bychkov, C Fiere, P Ianevski, B Yadav, ... Bioinformatics 36 (11), 3602-3604, 2020	88	2020
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid LeukemiaAML Functional Molecular Precision Medicine D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ... Cancer Discovery 12 (2), 388-401, 2022	86	2022
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling EI Andersson, S Pützer, B Yadav, O Dufva, S Khan, L He, L Sellner, ... Leukemia, 2017	86	2017
Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells P Gautam, L Karhinen, A Szwajda, SK Jha, B Yadav, T Aittokallio, ... Molecular cancer 15 (1), 1-16, 2016	70	2016
Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1 O Kauko, SY Imanishi, E Kulesskiy, L Yetukuri, TD Laajala, M Sharma, ... Journal of Biological Chemistry 295 (13), 4194-4211, 2020	58	2020
Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia JL Kivioja, A Thanasopoulou, A Kumar, M Kontro, B Yadav, MM Majumder, ... Leukemia 33 (6), 1360-1372, 2019	55	2019
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML D Malani, A Murumägi, B Yadav, M Kontro, S Eldfors, A Kumar, ... Leukemia 31 (5), 1187-1195, 2017	54	2017

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs